Targeting leukemic stem cells by breaking their dormancy

Mol Oncol. 2010 Oct;4(5):443-50. doi: 10.1016/j.molonc.2010.06.001. Epub 2010 Jun 9.


Transient or long-term quiescence, the latter referred to as dormancy are fundamental features of at least some adult stem cells. The status of dormancy is likely a critical mechanism for the observed resistance of normal HSCs and leukemic stem cells (LSCs) to anti-proliferative chemotherapy. Recent studies have revealed cytokines such as Interferon-alpha (IFNα) and G-CSF as well as arsenic trioxide (As(2)O(3)) to be efficient agents for promoting cycling of dormant HSCs and LSCs. Most interestingly, such cell cycle activated stem cells become exquisitely sensitive to killing by different chemotherapeutic agents, suggesting that dormant LSCs in patients may be targeted by a sequential two-step protocol involving an initial activation by IFNα, G-CSF or As(2)O(3), followed by targeted chemotherapy.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antineoplastic Agents / pharmacology
  • Arsenic Trioxide
  • Arsenicals / pharmacology
  • Drug Resistance, Neoplasm
  • Granulocyte Colony-Stimulating Factor / pharmacology
  • Humans
  • Interferon-alpha / pharmacology
  • Leukemia / pathology*
  • Neoplastic Stem Cells / drug effects
  • Neoplastic Stem Cells / pathology*
  • Oxides / pharmacology


  • Antineoplastic Agents
  • Arsenicals
  • Interferon-alpha
  • Oxides
  • Granulocyte Colony-Stimulating Factor
  • Arsenic Trioxide